What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?

What process do you follow when managing a patient receiving tarlatamab (bispecific antibody therapy) for ES SCLC?

• I personally treat these patients at my practice/health system from start to finish
• I refer these patients to another specialist within my practice/health system who manages bispecific antibody therapy from start to finish
• Refer out for entire course of therapy due to not comfortable managing side effects routinely (CRS, ICANS, etc)
• Refer out for entire course of therapy due to logistical limitations (eg coordination of hospitalization/monitoring/payment/follow up etc)
• Refer out for first 1-2 cycles due to logistical limitations, then resume subsequent treatments at my practice
• Refer out for first 1-2 cycles of therapy due to not comfortable managing initial side effects (CRS, ICANS, etc), then resume subsequent treatments at my practice
• Not recommending treatment with Tarlatamab until more data
• Other